# q04 rev 0 - removal probes (2026-10-06)

Each probe is a fresh blind-solver agent given a packet copied from this run's solver-1 packet minus
one marked document (text/, docs/ and manifest entry removed), in a neutrally named run folder bound
to the read guard, plus the verbatim question and a request for a single best two-decimal answer
with its probability if the packet does not settle it. Approximates the platform's document check.
Not an official blind solve. tested_sha256: 4fda6f2ac451ec3f1115bbe1b100a2b2bf2662eba2f5ed198ffcb10decdc3a00.
Gold: 20.33%.

## Without D12 (runs/q04-r0-probe-m7)

Return (verbatim, task notification 2026-10-06):

answer: Not answerable from this packet. The latest period in the packet ends March 31, 2026, and none of the documents covers the quarter or half-year ending June 30, 2026. If I must give a number, it is **20.04%**. That is the twelve months ended March 31, 2026, the latest that can be calculated. I put about a 5% chance on it being exactly right.

confidence: high that the packet can't settle this; low for any number.

path:
1. **The 2026 segment definition.** D11 (Q1 2026 release, dated 2026-05-01), text/D11.txt line 85: "The Company has recast its historical geographic segment information to conform to the reporting structure effective for the quarter ended March 31, 2026 … the skin health business (previously within the North America reportable operating segment) [has] been combined in a new Europe, Middle East &amp; Africa reportable operating segment."
2. **Q1 2026 North America** (D11 Table 4, "Three Months Ended March 31, 2026 2025"): net sales "| North America(1) | $ 888 | $ 904 |" (line 369), operating profit "| North America(1) | $ 141 | $ 197 |" (line 385).
3. **2025 under the 2026 definition** (D10, "Segment Information (Recast)"), in $ millions:

| Period | Net sales | Operating profit | D10 line |
| --- | --- | --- | --- |
| FY2025 | 3,679 | 790 | 25 |
| Q1 2025 | 904 | 197 | 160 |
| Q2 2025 | 919 | 187 | 222 |
| Six months 2025 | 1,823 | 384 | 245 |
| Q3 2025 | 922 | 199 | 312 |
| Nine months 2025 | 2,745 | 583 | 333 |

   The quarters add up to the six- and nine-month rows.
4. **Q4 2025, derived:** net sales 3,679 − 2,745 = 934; operating profit 790 − 583 = 207.
5. **The twelve months ended June 30, 2026** are Q3 2025 + Q4 2025 + Q1 2026 + Q2 2026:
   - Net sales: 922 + 934 + 888 + Q2 2026 = 2,744 + Q2 2026.
   - Operating profit: 199 + 207 + 141 + Q2 2026 = 547 + Q2 2026.
   - Q2 2026 is missing. A search of all text files for "June 30, 2026", "second quarter 2026", "Q2 2026" and similar terms found nothing. The manifest ends at D11.
6. **The forced number (twelve months ended March 31, 2026):**
   - Net sales: 3,679 − 904 + 888 = 3,663.
   - Operating profit: 790 − 197 + 141 = 734.
   - Margin: 734 / 3,663 = 20.038%, which rounds to 20.04%.
   - This would also be the June figure only if Q2 2026 exactly matched Q2 2025 (919 sales, 187 profit). Q1 2026 suggests otherwise: D11 line 104 shows North America at "$141 -28% 15.8% -590" (profit down 28%, margin down 590 basis points).

minimal_documents: D10 and D11 (the manifest confirms nothing later exists). No replacement exists. D09 and older documents use the pre-2026 definition, where North America still included skin health (FY2025 North America in D09: 4,045 sales, 784 profit).

readings:
- **Carry the Q1 2026 year-over-year trend into Q2 2026** (sales −1.8% from D11 line 70, profit −28% from line 104): Q2 2026 ≈ 902.5 sales and 134.6 profit. Twelve months: 681.6 / 3,646.5 = **18.69%**, about a 1% chance of being exact.
- **Hold Q2 2026 at the Q1 2026 margin** (15.88%): profit ≈ 143.3, giving 690.3 / 3,646.5 = **18.93%**, about a 1% chance.
- These trend estimates arguably come closer to the real figure, since Q1 2026 margins fell sharply. Even so, no single two-decimal value is likely to be exactly right.
- **Pre-2026 segment definition:** also not answerable (no Q2 2026 data), and it isn't what the question asks.

gaps:
- The decisive missing fact is North America net sales and operating profit for the quarter, or half-year, ending June 30, 2026 (the Q2 2026 release).
- Read in full: D01 (a 2019 stock-award agreement, not relevant), D09, D10 and D11.
- D02–D08 were only searched (for "North America", "2026", June 2026 terms and footnotes), not read in full. They are 2024–2025 releases under the older segment definitions.
- The D10 and D11 originals in docs/ were checked and match the extracted text.
- The packet's question.txt was deliberately not read. No layout files exist.

contaminated: no

Files used:
- D:\Dev\Docket\tasks\aq-docket-trial-02\runs\q04-r0-probe-m7\solver-1\text\D10.txt
- D:\Dev\Docket\tasks\aq-docket-trial-02\runs\q04-r0-probe-m7\solver-1\text\D11.txt
- D:\Dev\Docket\tasks\aq-docket-trial-02\runs\q04-r0-probe-m7\solver-1\text\manifest.json

Result: gold 20.33% not reached (forced 20.04% at about 5%). D12 needed.

## Without D10 (runs/q04-r0-probe-k3)

Summary of the verbatim return (task notification 2026-10-06; key lines quoted):
"The packet doesn't settle this exactly. My best estimate is **20.04%**, and I put about a 5% chance on it
being exactly right." The probe derived skin health's first-half 2025 contribution as old minus recast North
America (D07 2,025 / 390 vs D12 1,823 / 384 = 202 / 6), took the old-basis second half 2025 from D09 minus D07
(2,020 / 394) and assumed skin health's second half equalled its first half: 1,818 / 388 recast, then
721 / 3,597 = 20.0445%. Variants: 20.02% (Q3 + Q4 operating profit 393), 20.21% (skin health breaking even),
19.90% (Q2 run-rate); "A plausible range is roughly 19.9% to 20.2%." Wrong routes named: 18.32% (mixed
basis), 19.14% (old-basis second half), 18.72% (six months only). It noted "The manifest skips from D09 to
D11, so a D10 is absent" and that D12 points to the company's website for the recast history.
contaminated: no.

Result: gold 20.33% not reached (best 20.04% at about 5%; the true skin health second half was 164 / -12,
not the assumed 202 / 6). D10 needed.
